The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers
Open accessAbstract
BACKGROUND: Hepatitis B vaccine and hepatitis B immunoglobulin are considered for newborn infants of HBsAg-positive mothers to prevent hepatitis B infection. OBJECTIVES: To assess the beneficial and harmful effects of hepatitis B vaccines and hepatitis B immunoglobulin in newborn infants of HBsAg-positive mothers. SEARCH STRATEGY: Trials were identified through The Cochrane Neonatal Group Controlled Trials Register, The Cochrane Hepato-Biliary Group Controlled Trials Register, The Cochrane Central Register of Controlled Trials in The Cochrane Library, MEDLINE, and EMBASE (until February 2004), authors of trials, and pharmaceutical companies. SELECTION CRITERIA: Randomised clinical trials comparing: plasma-derived vaccine (PDV) or recombinant vaccine (RV) versus no intervention, placebo, or other active vaccines; hepatitis B immunoglobulin versus no intervention, placebo, or other control immunoglobulin; as well as PDV or RV plus hepatitis B immunoglobulin versus no intervention, placebo, or other control vaccines or immunoglobulin. DATA COLLECTION AND ANALYSIS: Outcomes are assessed at maximal follow-up. The primary outcome measure was hepatitis B occurrence, based on a blood specimen positive for HBsAg, HBeAg, or antibody to hepatitis B core antigen (anti-HBc). Binary outcomes are reported as relative risks (RR) with 95% confidence interval (CI). Subgroup analyses were performed with regard to methodological quality of the trial, mother's HBe-Ag status, and time of immunisation after birth. MAIN RESULTS: We identified 29 randomised clinical trials, five of which were considered high quality. Only three trials reported inclusion of hepatitis B e-antigen negative mothers. Compared with placebo/no intervention, vaccine reduced hepatitis B occurrence (RR 0.28, 95% confidence interval (CI) 0.20 to 0.40, 4 trials). No significant differences of hepatitis B occurrence were found comparing recombinant vaccine (RV) versus plasma-derived vaccine (PDV) (RR 1.00, 95% CI 0.71 to 1.42, 4 trials) and high-dose versus low-dose vaccine (PDV: RR 0.97, 95% CI 0.55 to 1.68, 3 trials; RV: RR 0.78, 95% CI 0.31 to 1.94, 1 trial). Compared with placebo/no intervention, hepatitis B immunoglobulin or the combination of vaccine plus hepatitis B immunoglobulin reduced hepatitis B occurrence (hepatitis B immunoglobulin: RR 0.50, 95% CI 0.41 to 0.60, 1 trial; PDV plus hepatitis B immunoglobulin: RR 0.08, 95% CI 0.03 to 0.17, 3 trials). Compared with vaccine, vaccine plus hepatitis B immunoglobulin reduced hepatitis B occurrence (RR 0.54, 95% CI 0.41 to 0.73, 10 trials). Hepatitis B vaccine and hepatitis B immunoglobulin seem safe, but few trials reported on adverse events. AUTHORS' CONCLUSIONS: Vaccine, hepatitis B immunoglobulin, and vaccine plus hepatitis B immunoglobulin prevent hepatitis B occurrence in newborn infants of HBsAg positive mothers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Evaluating non-randomised intervention studies
Deeks, J., Dinnes, J., D'Amico, R., Sowden, A., Sakarovitch, C., Song, F., Petticrew, M., & Altman, D. (2003) · Health Technology Assessment · doi:10.3310/hta7270 · Cited by 2,907
Risk of anaphylaxis after vaccination of children and adolescents.
Bohlke, K., Davis, R. L., Marcy, S. M., Braun, M. M., DeStefano, F., Black, S. B., Mullooly, J. P., Thompson, R. S., & for the Vaccine Safety Datalink Team (2003) · PEDIATRICS · doi:10.1542/peds.112.4.815 · Cited by 320
Cited by
Global burden of hepatitis B virus: current status, missed opportunities and a call for action
Hsu, Y.-C., Huang, D. Q., & Nguyen, M. H. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00760-9 · Cited by 632
Tenofovir to Prevent Hepatitis B Transmission in Mothers with High Viral Load
Pan, C. Q., Duan, Z., Dai, E., Zhang, S., Han, G., Wang, Y., Zhang, H., Zou, H., Zhu, B., Zhao, W., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508660 · Cited by 573
Evidence-based clinical guidelines for immigrants and refugees
Pottie, K., Greenaway, C., Feightner, J., Welch, V., Swinkels, H., Rashid, M., Narasiah, L., Kirmayer, L. J., Ueffing, E., MacDonald, N. E., et al. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.090313 · Cited by 526
Lee, C., Gong, Y., Brok, J., Boxall, E. H., & Gluud, C. (2006) · BMJ · doi:10.1136/bmj.38719.435833.7c · Cited by 402
Self-citationJoshi, D., James, A., Quaglia, A., Westbrook, R. H., & Heneghan, M. A. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61495-1 · Cited by 385
Metadata
- Authors
- Lee, C., Gong, Y., Brok, J., Boxall, E. H., & Gluud, C.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2006-04-19
- Volume
- 2010
- Issue
- 1
- Pages
- CD004790-CD004790
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2162425027
- Cited by
- 184
- References
- 4
- FWCI
- 3.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. https://app.cochat.ai/papers/10.1002/14651858.cd004790.pub2
- The paper
- Lee, C., Gong, Y., Brok, J., Boxall, E. H., & Gluud, C. (2006). Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd004790.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.